Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vaughn Smider
Scripps Research Institute, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sevion Therapeutics (formerly known as Fabrus)
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Smider founded Fabrus, a pharmaceutical company focused on the development of novel monoclonal antibodies that merge human IgG scaffolds with uniquely structured cow CDR3s. Fabrus also developed an antibody delivery system, and high through-put antibody screening technologies. Fabrus recently merged together with Senesco Technologies, now renamed as Sevion Therapeutics, a publicly traded company, that couples Fabrus technology with cancer therapeutics based on a proprietary platform in eukaryotic translations initiation Factor 5a. The funded research is utilizing the Fabrus-directed screening technology to identify cow antibodies, creating a reportable Financial Conflict of Interest.
Antibody Fingerprinting of Triple Negative Breast Cancer by High Throughput FACS
This project addresses an unmet clinical need in breast cancer, where approximately 20% of patients are diagnosed with 'Triple Negative' tumors that have a poor prognosis and lack targeted therapies. The study will screen triple negative breast cancer cells against human and cow antibody libraries that are designed in a novel way and include unique antibody structures that can recognize previously unidentified molecules at the tumor cell surface. The results could identify targets in triple negative breast cancer, improve understanding of the disease, and generate antibodies for diagnosis and treatment.
Filed on July 29, 2015.
Tell us what you know about Vaughn Smider's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Vaughn Smider filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Vaughn Smider | Scripps Research Institute | Conflict of Interest | The Scripps Research Institute | >$600,000 |
| Vaughn Smider | Scripps Research Institute | Conflict of Interest | Sevion Therapeutics (formerly known as Fabrus) | $200,000 - $249,999 |
| Vaughn Smider | Scripps Research Institute | Conflict of Interest | The Scripps Research Institute | $200,000 - $249,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.